BLA Submitted for Brentuximab Vedotin for Hodgkin and Anaplastic Large Cell Lymphomas - ONA
Links shared publicly online about this topic.
- 471total visits
BLA Submitted for Brentuximab Vedotin for Hodgkin and Anaplastic Large Cell Lymphomas - ONA
View full resource at oncologynurseadvisor.com
Tags: Genetic, Cancer, Lymphoma, Hodgkin Lymphoma, FDA, Genetics
Most Recently Shared on March 1, 2011 at 5:25 pm By:
BLA Submitted for Brentuximab Vedotin for Hodgkin and Anaplastic Large Cell Lymphomas http://goo.gl/fb/6ZBhe
Seattle Genetics Submits BLA to FDA for Brentuximab Vedotin in Relapsed or Refractory Hodgkin Lymphoma and Systemic ALCL
drugs.com — “Brentuximab vedotin is a new drug in development for the treatment of Hodgkin's lymphoma and anaplastic large cell lymphoma. Brentuximab vedotin information includes news, clinical trial results and side effects.” View full resource at drugs.com
Most Recently Shared on March 9, 2011 at 10:17 pm By:
Drugs and Devices OW OW Health
Seattle Genetics Submits BLA to FDA for Brentuximab Vedotin in Relapsed or Refractory Hodgkin Lymphoma and... http://bit.ly/hi82SU #drug
BLA Submitted for Brentuximab Vedotin for Hodgkin and Anaplastic Large Cell Lymphomas - MPR
empr.com — “Seattle Genetics announced that it has submitted a Biologics License Application (BLA) to the FDA for the use of brentuximab vedotin (SGN-35) to treat relapsed or refractory Hodgkin lymphoma and relapsed or refractory systemic anaplastic large cell lymphoma.” View full resource at empr.com
Most Recently Shared on March 1, 2011 at 5:17 pm By:
MPR News: BLA Submitted for Brentuximab Vedotin for Hodgkin and Anaplastic Large Cell Lymphomas: Seattle Genetic... http://bit.ly/eZo3Yj
Seattle Genetics submits brentuximab vedotin BLA to FDA for treatment of ALCL, Hodgkin lymphoma
news-medical.net — “Seattle Genetics, Inc. announced today that it has submitted a Biologics License Application to the U.S. Food and Drug Administration for the use of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma and relapsed or refractory systemic anaplastic large cell lymphoma.” View full resource at news-medical.net
Most Recently Shared on February 28, 2011 at 4:49 pm By:
News-Medical.Net Health News and Oncology
Oncology News: Seattle Genetics submits brentuximab vedotin BLA to FDA for treatment of ALCL, Hodgkin lymphoma: ... http://bit.ly/icy47R
Advertisement
